GlassScriptPhysician profile
Dilip L Solanki
NPI 1124060116
$16,196.82
in general payments reported to CMS, 2019-2025
36 companies · $51.18 in 2025
The $51.18 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $349 · 2021: $672 · 2022: $233 · 2023: $248 · 2025: $51.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $4,905.63 | 2019 | |
| Kyowa Kirin, INC. | $4,839.39 | 2019 | |
| Seagen INC. | $1,652.94 | 2019 | |
| Merck Sharp & Dohme LLC | $431.99 | 2019 | |
| Janssen Biotech, INC. | $428.87 | 2019-2021 | |
| Abbvie INC. | $384.52 | 2019-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $363.43 | 2019-2020 | |
| Tesaro, INC. | $264.13 | 2019 | |
| Astellas Pharma US INC | $261.10 | 2019 | |
| Puma Biotechnology, INC. | $240.15 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $233.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.83 | 2019 | |
| Rigel Pharmaceuticals, INC. | $183.57 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.73 | 2019 | |
| Pfizer INC. | $150.49 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $149.10 | 2019-2021 | |
| Array Biopharma INC | $131.78 | 2019 | |
| Incyte Corporation | $131.44 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $128.61 | 2019-2021 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Trodelvy |
| Karyopharm Therapeutics INC. | $121.38 | 2022 | |
| Glaxosmithkline, LLC. | $111.15 | 2022 | |
| Heron Therapeutics, INC. | $109.83 | 2019 | |
| Celgene Corporation | $109.32 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $86.57 | 2019 | |
| Amgen INC. | $38.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.60 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.72 | 2019 | |
| Genentech USA, INC. | $14.43 | 2019 | |
| Lilly USA, LLC | $13.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2019 | |
| Tersera Therapeutics LLC | $13.34 | 2019 | |
| Taiho Oncology, INC. | $12.49 | 2019 | |
| Emd Serono, INC. | $12.47 | 2019 | |
| Clovis Oncology, INC. | $9.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Solanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.